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ABSTRACT:
Cannabinoid type 1 (CB1) receptor antagonists have been devel-
oped for the treatment of obesity, but a major disadvantage is that
they cause unwanted psychiatric effects. Selective targeting of
peripheral CB1 receptors might be an option to circumvent these
side effects. Multidrug resistance-associated proteins (MRPs) can
influence the pharmacokinetics of drugs and thereby affect their
disposition in the body. In this study, we investigated the interac-
tion of the prototypic CB1 receptor antagonist rimonabant and a
series of 3,4-diarylpyrazoline CB1 receptor antagonists with MRP1,
MRP2, MRP3, and MRP4 in vitro. Their effect on ATP-dependent
transport of estradiol 17--D-glucuronide (E217G) was measured
in inside-out membrane vesicles isolated from transporter-overex-
pressing human embryonic kidney 293 cells. Rimonabant inhibited
MRP1 transport activity more potently than MRP4 (Ki of 1.4 and 4
M, respectively), whereas the 3,4-diarylpyrazolines were stronger
inhibitors of MRP4- than MRP1-mediated transport. A number of
CB1 receptor antagonists, including rimonabant, stimulated MRP2
and MRP3 transport activity at low substrate concentrations but
inhibited E217G transport at high substrate concentrations. The
interaction of 3,4-diarylpyrazolines and rimonabant with MRP1–4
indicates their potential for drug-drug interactions. Preliminary in
vivo data suggested that for some 3,4-diarylpyrazolines the rela-
tively lower brain efficacy may be related to their inhibitory potency
against MRP4 activity. Furthermore, this study shows that the
modulatory effects of the 3,4-diarylpyrazolines were influenced by
their chemical properties and that small variations in structure can
determine the affinity of these compounds for efflux transporters
and thereby affect their pharmacokinetic behavior.
Introduction
The cannabinoid type 1 (CB1) receptor is involved in regulation of
feeding behavior, metabolism and energy balance (Di Marzo, 2008).
Studies in rodents have shown that antagonism of this receptor leads to
reduced food intake and weight reduction (Boyd and Fremming, 2005).
Several CB1 receptor antagonists were developed for the treatment of
obesity, and clinical studies showed a reduction in appetite, weight loss,
and improved metabolic risk factors (Boyd and Fremming, 2005; Bifulco
et al., 2009). Rimonabant was the first and only selective CB1 receptor
antagonist approved for therapeutic use. However, the drug was with-
drawn from the market within 2 years of its introduction, because psy-
chiatric adverse effects, in particular depression, were revealed in addi-
tional clinical studies (Jones, 2008; Nissen et al., 2008).
The CB1 receptor is expressed in brain and peripheral tissues such
as adipose, skeletal muscle, liver, gut, and pancreas (Di Marzo, 2008).
In the brain, activation of the endocannabinoid system appears to be
involved in coping with stress and anxiety. Therefore, the psychiatric
side effects seen for CB1 receptor antagonists could be due to inhi-
bition of the endocannabinoid system (Bifulco et al., 2009). It is
believed that the positive effect of antagonists on metabolic factors
could also be mediated via peripheral CB1 receptors (Di Marzo,
2008). Indeed, a recent study with a peripheral CB1 receptor antag-
onist in obese mice showed that this antagonist could improve the
cardiometabolic risk in these mice without inhibition of the central
CB1 receptor (Tam et al., 2010). Therefore, peripheral CB1 receptor
antagonists might have therapeutic potential for improving metabolic
risk in obese patients without causing psychiatric side effects.
Multidrug resistance-associated proteins (MRPs) are efflux trans-
porters that can influence drug disposition by transporting a wide
variety of substrates out of the cell (Zhou et al., 2008), preventing
drugs from entering specific tissues or organs (e.g., intestine and
brain), or increasing elimination of compounds, e.g., via liver and
kidney (Yu et al., 2007). MRP1, MRP2, MRP3, and MRP4 belong to
the ATP-binding cassette (ABC) transporter subfamily C and have
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overlapping substrate specificities (Kruh and Belinsky, 2003). MRP1
is present in many tissues, with the highest protein expression in lung,
adrenal gland, heart, and skeletal muscle, and lower amounts in brain,
choroid plexus, spleen, kidney, intestine, testes, placenta, and liver
(Flens et al., 1996; Rao et al., 1999; Nies et al., 2004; Leslie et al.,
2005). It is expressed basolaterally in most tissues, but it has an apical
localization in brain capillary endothelial cells (Nies et al., 2004;
Leslie et al., 2005). MRP2 is highly expressed in liver, and lower
expression levels can be found in the apical membranes of kidney
tubules, gastrointestinal tract, gallbladder, placenta, and bronchi (van
Aubel et al., 2000; Nies and Keppler, 2007). MRP3 is expressed in
kidney, colon, small intestine, liver, and gallbladder, where it is found
mostly in basolateral membranes (Scheffer et al., 2002). MRP4 is
widely distributed in tissues and blood cells and has a dual membrane
localization, which is basolateral in prostate tubuloacinar cells, hepa-
tocytes, and choroid plexus, and apical in kidney proximal tubule cells
and brain capillary endothelium (Nies et al., 2004; Russel et al., 2008).
The expression of MRP1–4 at locations that are involved in drug
disposition and penetration suggests that they influence drug concen-
trations in plasma and different organs, and because of their presence
in the blood-brain-barrier and choroid plexus, MRP4 and MRP1 might
play a role in restricting CB1 receptor antagonists from the brain.
Interaction of a drug with efflux transporters not only can influence
its own pharmacokinetics, but it also can change the disposition of
other compounds that are substrates for the same transporter. Studies
describing the interaction of CB1 receptor antagonists with MRP1–4
may give information not only on the pharmacokinetics of these
antagonists but also on possible drug-drug interactions. Here, we
investigated the in vitro effect of a series of 3,4-diarylpyrazoline CB1
receptor antagonists (Fig. 1) (Lange et al., 2005) and the prototypic
CB1 receptor antagonist rimonabant on MRP1–4 transport activity. In
addition, for some 3,4-diarylpyrazolines, we related their transporter
interaction to preliminary in vivo pharmacodynamic effects measured
in rats.
Materials and Methods
Materials. [6,7-3H(N)]Estradiol 17--D-glucuronide (41.8 Ci/mmol) was
purchased from PerkinElmer Life and Analytical Sciences (Groningen, The
Netherlands). Bac-to-Bac and Gateway systems, Dulbecco’s modified Eagle’s
medium  GlutaMAX-I culture medium, and fetal calf serum were purchased
from Invitrogen (Breda, The Netherlands). Triple flasks (500 cm2) were
purchased from Sanbio BV Biological Products (Uden, The Netherlands).
Estradiol 17--D-glucuronide (E217G), adenosine 5-triphosphate magne-
sium salt (from bacterial source), and adenosine 5-monophosphate monohy-
drate (from yeast) were purchased from Sigma-Aldrich (Zwijndrecht, The
Netherlands). Protein concentrations were determined with a Bio-Rad protein
assay kit from Bio-Rad Laboratories (Veenendaal, The Netherlands). Mono-
clonal mouse-anti-human MRP3 antibody M3II-21 was purchased from Ab-
cam (Cambridge, UK). Monoclonal mouse-anti-human MRP1 (QCRL-1) was
kindly provided by Dr. S. P. C. Cole (Queen’s University Cancer Research
Institute, Kingston, ON, Canada). 3,4-Diarylpyrazoline CB1 receptor antago-
nists (Lange et al., 2005) and rimonabant were kindly provided by Abbott
Healthcare Products (Hannover, Germany).
Generation of Baculovirus. Full-length human MRP1, MRP2, and MRP3
were cloned separately into the Gateway pDONR221vector. The sequence of
MRP1 was equal to GenBank accession number NM_004996 except for three
silent mutations at base pairs 1684, 1704, and 4002, which are known poly-
morphisms (Conrad et al., 2001). The sequence of MRP2 was equal to
FIG. 1. Chemical structure of CB1 receptor antagonists. Core
structure of 3,4-diarylpyrazoline derivatives 4, 11 to 17, and 23 (A)
with the chemical structures of R for the N-substituent of these
compounds (B) (Lange et al., 2005). C, structure of rimonabant.
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NM_000392 except for three silent mutations at base pairs 264, 1167, and
3972, of which C3972T is a known polymorphism (Ito et al., 2001), and the
sequence of MRP3 was equal to NM_003786. Consequently, constructs were
also cloned into a VSV-G improved pFastBacDual vector for mammalian cell
transduction using the Gateway system (El-Sheikh et al., 2007). Full-length
human MRP4 and enhanced yellow fluorescent protein (eYFP), which was
used as a negative control, were cloned previously (El-Sheikh et al., 2007).
Baculoviruses were produced as described in the Bac-to-Bac manual
(Invitrogen).
Cell Culture and Transduction of HEK293 Cells. HEK293 cells were
grown in Dulbecco’s modified Eagle’s medium-GlutaMAX-I supplemented
with 10% fetal calf serum at 37°C under 5% CO2-humidified air. HEK293
cells were cultured in 500 cm2 triple flasks until 40% confluent, after which
culture medium was removed and 25 ml of medium and 10 ml of eYFP,
MRP1, MRP2, MRP3, or MRP4 baculovirus was added. Cells were incubated
for 15 min at 37°C, after which a further 40 ml of medium was added, and 5
mM sodium butyrate was added 24 h after transduction. Three days after
transduction, cells were harvested by centrifugation at 5000g for 5 min.
Isolation of Membrane Vesicles and Protein Analysis. Membranes were
isolated according to a previously described method with slight modifications
(El-Sheikh et al., 2008). In brief, harvested cell pellets were resuspended in
ice-cold homogenization buffer (0.5 mM sodium phosphate and 0.1 mM
EDTA) supplemented with protease inhibitors (100 M phenylmethylsulfonyl
fluoride, 5 g/ml aprotinin, 5 g/ml leupeptin, 1 g/ml pepstatin, and 1 M
N-(trans-epoxysuccinyl)-L-leucine 4-guanidinobutylamide (E-64) and shaken
at 4°C for 30 min. Lysed cells were centrifuged at 100,000g for 30 min at 4°C,
and the pellets were homogenized in ice-cold TS buffer (10 mM Tris-HEPES and
250 mM sucrose, pH 7.4) supplemented with protease inhibitors described above,
using a tight-fitting Dounce homogenizer for 25 strokes. After centrifugation at
1000g for 20 min at 4°C, the supernatant was centrifuged at 100,000g for 60 min
at 4°C. The resulting pellet was resuspended in TS buffer without protease
inhibitors and passed through a 27-gauge needle 25 times. Protein concentration
was determined by a Bio-Rad protein assay kit. Crude membrane vesicles were
dispensed in aliquots, frozen in liquid nitrogen, and stored at 80°C until
further use.
Western Blotting. Membrane vesicle preparations were solubilized in
SDS-polyacrylamide gel electrophoresis sample buffer and separated on SDS
gel containing 7.5% acrylamide according to Laemmli. Then, they were blotted
on nitrocellulose membrane using the iBlot dry blotting system (Invitrogen).
Monoclonal mouse-anti-human MRP1 (QCRL-1, 1:700) and MRP3 (M3II-21,
1:200) antibodies and affinity-purified, polyclonal rabbit-anti-human MRP2
(polyclonal antibody hM2-p2, 1:500) and MRP4 (polyclonal antibody hM4-p4,
1:1000) (van Aubel et al., 2002; Smeets et al., 2004) were used to detect
transporters. The secondary antibodies used in 1:10,000 dilution were fluores-
cent goat-anti-mouse IRdye800 (Rockland Immunochemicals, Gilbertsville,
PA) and goat-anti-rabbit Alexa Fluor 680 (Invitrogen). Signals were visualized
using the Odyssey imaging system (Li-Cor Biosciences, Lincoln, NE).
Vesicular Transport Assays. Uptake of [3H]E217G into membrane ves-
icles was performed using a rapid filtration technique (van Aubel et al., 1999).
The 30-l reaction mix consisted of TS buffer, 4 mM ATP, 10 mM MgCl2,
E217G, and 7.5 g of membrane vesicles; 0.1 (MRP1), 0.15 (MRP2, MRP4),
and 0.2 Ci (MRP3) of [3H]E217G was used, supplemented with unlabeled
E217G to concentrations indicated in legends. The reaction was started when
the mixture was incubated at 37°C and then stopped by placing samples on ice
and adding 150 l of ice-cold TS buffer. A MultiScreenHTS-HV, 0.45-m,
polyvinylidene difluoride 96-well filter plate was prewashed with TS buffer,
and diluted samples were filtered through this filter plate using a Multi-
ScreenHTS vacuum manifold filtration device (Millipore, Etten-Leur, The
Netherlands). The filters were washed twice with TS buffer and were then
separated from the plate. After addition of 2 ml of scintillation fluid to each
filter and subsequent liquid scintillation counting, uptake of [3H]E217G into
membrane vesicles was determined by measuring radioactivity associated with
the filters. In control experiments, ATP was substituted with AMP. Net
ATP-dependent transport was calculated by subtracting values measured in the
presence of AMP from those measured in the presence of ATP. Time-
dependent transport was found to be linear up to 5 min for MRP1, MRP2, and
MRP4 and up to 3 min for MRP3 (results not shown).
Vesicular Interaction Assays. To evaluate the inhibitory effects of 3,4-
diarylpyrazolines and rimonabant on [3H]E217G uptake in MRP1, 2, 3, and
4 inside-out membrane vesicles, the above-mentioned transport assay was
performed in the absence or presence of 10 and 100 M CB1 receptor
antagonists. The concentration-dependent effect of 1 to 100 M concentrations
of compounds 13, 15, and rimonabant was measured at three different E217G
concentrations: 0.16, 1, and 5 M for MRP1; 2, 20, and 200 M for MRP2;
0.08, 1, and 5 M for MRP3; and 0.1, 0.3, and 1 M for MRP4. ATP-
dependent transport was calculated.
Determination of Actual Concentrations of 3,4-Diarylpyrazolines and
Rimonabant with LC-MS/MS. The actual amount of CB1 receptor antago-
nists dissolved under vesicular transport assay conditions was measured. eYFP
vesicles (7.5 g) were added in each well to mimic the vesicle environment.
The reaction mixture without [3H]E217G was added on ice and only the AMP
condition was measured. The 96-well plate was mixed, and the total reaction
mixture from one well was transferred to an Eppendorf tube at room temper-
ature. Sample was spun down at maximal speed (16,000–20,000g) for 5
min at room temperature and 10 l of supernatant was reconstituted in 50%
acetonitrile-water and 0.1% trifluoroacetic acid (TFA) before LC-MS/MS
analysis. Actual concentrations were determined using an Accela ultrahigh-
performance liquid chromatograph (Thermo Fisher Scientific, Waltham, MA)
coupled to a TSQ Vantage (Thermo Fisher Scientific) triple quadrupole mass
spectrometer. The CB1 receptor antagonists were separated on a Zorbax
Eclipse Plus column (50  2.1 mm, 1.8-m particle size; Agilent Technolo-
gies, Santa Clara, CA). The elution gradient was as follows: 0 min, 50% B; 5
min, 90% B; and 6 min, 50% B. Solvent A consisted of 0.1% TFA in ultrapure
water, and solvent B consisted of 0.1% TFA in acetonitrile. The column
temperature was set at 40°C, and the flow rate was 200 l/min. The effluent
from the high-performance liquid chromatograph was passed directly into the
electrospray ion source. Positive electrospray ionization was achieved using a
nitrogen sheath gas with ionization voltage at 4 kV. The capillary temperature
was set at 350°C. Detection of each analyte was based on isolation of the
protonated molecular ion, [M  H], and subsequent MS/MS fragmentations
and selected reaction monitoring were performed. The conditions per com-
pound are summarized in Table 1. CB1 receptor antagonist 4 or 16 was used
as an internal standard, and the response ratio of test compound to internal
standard was used to determine the concentration. The actual assay concen-
tration of compound was measured in duplicate in at least three independent
experiments.
In Vivo Pharmacodynamic Effect of 3,4-Diarylpyrazolines on CP55,940-
Induced Hypotension in Rat. The ED50 of 3,4-diarylpyrazolines for attenua-
tion of 5-(1,1-dimethylheptyl)-2-[5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]
phenol (CP55,940)-induced hypotension in male, normotensive, anesthetized Wistar
rats was determined according to a method described previously using different
intravenous doses (n  2 per dose) of CB1 receptor antagonists 10 min before
CP55,940 (0.1 mg/kg i.v.) administration (Lange et al., 2004). Hypotension was
achieved within 1 min after administration of the CB1 receptor agonist CP55,940, and
the lowest blood pressure was the measure of the hypotensive effect. ED50 was
calculated on the linear part of the percentage dose-response curve and is the dose of
antagonist that inhibited the hypotensive effect of CP55,940 by 50%. Experiments
TABLE 1
LC-MS/MS conditions for detection of CB1 receptor antagonists
Compound RetentionTime
Parent
(m/z)
Collision Energy (m/z)
S Lens
Product 1 Product 2
min eV
4 3.2 420.182 255.060 (27) 375.140 (13) 115
11 4.2 448.222 255.100 (26) 375.080 (16) 108
12 4.2 448.221 255.060 (30) 375.050 (14) 111
13 3.8 434.204 255.060 (26) 375.090 (14) 109
14 3.5 446.205 255.090 (28) 375.100 (16) 118
15 4.8 474.245 255.070 (29) 375.100 (28) 127
16 5.4 488.261 255.060 (31) 375.090 (19) 130
17 4.0 478.184 255.050 (28) 375.000 (15) 113
23 2.6 510.169 255.080 (29) 375.100 (15) 127
Rimonabant 3.2 463.163 299.000 (46) 363.020 (29) 125
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were approved by the local ethics committee on animal experimentation at Solvay
Pharmaceuticals (Weesp, The Netherlands).
Kinetic Analysis. All data are expressed as means  S.E.M. Curve-fitting
of the resulting concentration-dependent transport curves and determination of
IC50 values for the CB1 receptor antagonists was performed by nonlinear
regression analysis using GraphPad Prism software (version 5.02; GraphPad
Software Inc., San Diego, CA). The following equation was fitted to the data:
y bottom (top bottom)/(1 10(logIC50x)  Hill slope), in which x is the log
inhibitor concentration and y is expressed as uptake versus control (percent-
age). A Michaelis-Menten fit was used for MRP1, MRP3, and MRP4 E217G
curves, and an allosteric sigmoidal fit was used for MRP2. Log (inhibitor or
stimulator) versus response with variable slope was used to plot the inhibition
and stimulation curves with 13, 15, or rimonabant. Results of the inhibition
assay for interaction of MRP1/4 with 13 and rimonabant were analyzed
using Dixon’s method combined with linear regression analysis to estimate
the inhibitory constant (Ki). Statistical differences were determined using
one-way analysis of variance with Dunnett’s multiple comparison test in
GraphPad Prism. Differences were considered to be significant at p  0.05.
Results
Expression of MRP1, MRP2, MRP3, and MRP4 in Isolated
Membrane Vesicles. Immunoblot analysis performed on membrane
vesicles from HEK293 cells overexpressing MRP1, MRP2, MRP3,
and MRP4 demonstrated that all four transporters were successfully
expressed (data not shown). MRP1 seemed to be less glycosylated as
indicated by a band at 160 kDa, but this had no influence on its
transport activity (Fig. 2A). The negative control, consisting of mem-
brane vesicles from eYFP-overexpressing HEK293 cells, showed no
expression of MRP1–4.
Concentration-Dependent Transport of E217G into MRP1-,
MRP2-, MRP3-, and MRP4-Overexpressing Membrane Vesicles.
Concentration-dependent uptake of E217G into membrane vesicles
was measured after 5 min for all transporters, and typical curves are
shown in Fig. 2, A to D. ATP-dependent E217G transport reached
maximal activities (Vmax) of 31  1, 2220  100, and 94  5 pmol 
mg1  min1 for MRP1, MRP3, and MRP4, respectively. The
affinity of E217G (Km) for MRP1, MRP3, and MRP4 was 7.5 0.1,
56 6, and 15 3 M, respectively. Repetition of the experiment for
each transporter gave comparable kinetic parameters; only the Vmax of
MRP3 varied between different batches of membrane vesicles, because
of different expression levels of the transporter. Transport activity of
MRP2 followed a sigmoidal relationship with increased E217G con-
centration (Fig. 2B). A Hill slope of 1.6 0.03 was calculated for MRP2
activity, which is indicative of positive cooperativity.
Effects of 3,4-Diarylpyrazolines and Rimonabant on MRP1-,
MRP2-, MRP3-, and MRP4-Mediated E217G Transport. Based
on the kinetics of E217G uptake by MRP1–4, the following E217G
concentrations, well below the Km, were chosen for interaction studies
with 3,4-diarylpyrazolines and rimonabant (Fig. 1): 0.16 M for
MRP1, 20 M for MRP2, 0.08 M for MRP3, and 0.12 M for
MRP4. In the case of MRP2, 20 M substrate was used to measure
both stimulation and inhibition.
Figure 3 shows the effect of 10 and 100 M concentrations of the CB1
receptor antagonists on E217G transport by MRP1–4. Because of poor
solubility, the actual concentrations of the 3,4-diarylpyrazolines and
rimonabant were 3- to 100-fold lower than the predicted concentrations
(see legend to Fig. 3). The highest concentration of the series of 3,
4-diarylpyrazolines inhibited MRP4 transport activity (Fig. 3D) more
potently than MRP1 activity (Fig. 3A). Of the 3,4-diarylpyrazolines,
compounds 4 and 12 to 14 significantly inhibited MRP1- and MRP4-
mediated E217G transport. Compound 13 had the highest inhibitory
effect on both transporters, with34 13 and72 8% for MRP1 and
MRP4, respectively. Transport of E217G by MRP1 and MRP4 was not
inhibited by compounds 15 to 17 and 23, whereas compound 11 did
inhibit MRP4, but not MRP1. Rimonabant inhibited MRP1 more po-
tently than MRP4, viz.84 4 versus58 3% (Fig. 3, A and D). In
contrast to MRP1 and MRP4, MRP2 transport activity was stimulated by
most compounds at both concentrations tested (Fig. 3B). At the lower
concentration, compounds 15 to 17 significantly increased uptake of
E217G into MRP2 vesicles (256–305%). Stimulation of MRP2 was
strongest at the high concentration of compounds 4 to 14 (543–734%)
and less by compounds 15 to 17 (349–412%) and rimonabant (513%).
FIG. 2. Kinetics of ATP-dependent E217G
transport into membrane vesicles of HEK293
cells overexpressing MRP1 (A), MRP2 (B),
MRP3 (C), or MRP4 (D). Concentration-depen-
dent E217G transport was determined after 5
min for all transporters. ATP-dependent eYFP
values were subtracted from corresponding
ATP-dependent MRP values, and Km and Vmax
were determined by nonlinear regression anal-
ysis. Data points represent the mean  S.E.M.
of triplicate measurements in a representative
experiment.
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Compound 23 did not significantly increase transport. Figure 3C shows
that, although E217G itself inhibited transport, MRP3-mediated
E217G transport was significantly stimulated by rimonabant and most
3,4-diarylpyrazolines, of which compounds 11 and 13 had the highest
stimulatory effect (155%).
Mechanism of Modulation of MRP1–4 Transport by Com-
pounds 13, 15, and Rimonabant. To get a better understanding of the
mechanism of interaction, we measured concentration-dependent ef-
fects of certain CB1 receptor antagonists on MRP1–4 transport at
three different E217G concentrations for each transporter (Fig. 4).
3,4-Diarylpyrazoline derivatives 13 and 15 and rimonabant were
selected for further investigation because the magnitude of their
effects on the transport activity were different.
Increasing E217G concentrations did not decrease the potency of
3,4-diarylpyrazolines 13 and 15 and rimonabant for inhibiting MRP1
and MRP4 (Fig. 4, A–C and J–L); the percentage of inhibition and the
IC50 values of 13 and rimonabant for MRP4 and MRP1 were similar
at different E217G concentrations. Dixon plots for 13- and rimon-
abant-mediated inhibition of MRP4 and MRP1 show that the lines
intersected virtually at the x-axis for both compounds, which is
indicative of noncompetitive inhibition (Fig. 5, A–C). The intersec-
tions corresponded to a Ki of 1.4 M rimonabant for MRP1, 4
FIG. 3. Effect of CB1 receptor antagonists on ATP-dependent
transport of E217G into MRP1- (A), MRP2- (B), MRP3- (C), or
MRP4-overexpressing (D) membrane vesicles. Transport was mea-
sured during 5 min at concentrations of 0.16, 20, 0.08, and 0.12 M
E217G, for MRP1, MRP2, MRP3, and MRP4, respectively, in the
absence () or presence of CB1 receptor antagonists. Because of
their poor solubility, concentrations in the low range varied between
0.4 and 2.2 M (u) and between 4 and 33 M (f) for the 10-fold
higher range. Actual concentrations of CB1 receptor antagonists
corresponding to the gray bars were 2.2 M for compound 4, 0.7 to
1.3 M for compounds 11 to 17 and 23, and 0.4 M for rimon-
abant. Actual concentrations corresponding to the black bars were
33 M for CB1 receptor antagonist 4, 7 M for compounds 11 and
12, 12 M for compounds 13 and 14, 1 to 3 M for compounds 15
to 17 and 23, and 4 M for rimonabant. ATP-dependent uptake in
the absence of CB1 receptor antagonists was set at 100% () and
was also measured in the presence of 100 M E217G (f).
Means  S.E.M. of three independent experiments are shown.
Statistically significant differences from vehicle control: , p 
0.05; , p  0.01; , p  0.001.
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M rimonabant for MRP4, and 7 M 13 for MRP4. 3,4-
Diarylpyrazoline 15 did not inhibit MRP1 transport activity at any of
the concentrations tested and only moderately inhibited MRP4 (Fig. 4,
A–C and J–L).
MRP2-mediated transport was stimulated by compounds 13, 15,
and rimonabant at the lowest E217G concentration of 2 M (Fig.
4D). Stimulation was decreased at 20 M E217G, and transport was
inhibited at 200 M E217G (Fig. 4, D–F). Rimonabant and com-
pound 15 appeared to have the same stimulatory and inhibitory
potency on MRP2-mediated transport.
MRP3-mediated E217G transport was stimulated at a low sub-
strate concentration, which gradually disappeared at higher substrate
concentrations (Fig. 4, G–I). At a concentration of 15 M E217G,
high concentrations of compounds 13 and 15 and rimonabant inhib-
ited E217G transport via MRP3 (data not shown).
In Vivo Pharmacodynamic Effect of 3,4-Diarylpyrazolines on
CP55,940-Induced Hypotension in Rat. To get an impression of the
relative brain penetration of the 3,4-diarylpyrazolines, the CB1 recep-
tor-mediated blood pressure effect of compounds 4, 11, 14, and 15
was compared with their in vitro CB1 receptor binding affinity. For
this purpose, in rats, we measured the initial rapid effect of CB1
receptor antagonists on CP55,940-induced hypotension, which is con-
sidered to originate primarily from a central sympathetic response
(Vollmer et al., 1974). Table 2 describes the effective intravenous
dose (ED50) that was needed for 50% inhibition of the hypotensive
effect of CP55,940 and the binding affinity (expressed as Ki) of these
compounds for the CB1 receptor, as determined previously (Lange et al.,
2005). The in vivo data show that CB1 receptor antagonist 15 had the
lowest ED50 value. If the ED50 of 15 relative to its binding affinity is
extrapolated to compounds 4, 11, and 14 on basis of their Ki values for
FIG. 4. Effect of CB1 receptor antagonists 13 (), 15 (Œ, – – –), and rimonabant (F) on MRP-mediated E217G transport at different substrate concentrations. E217G
concentrations were 0.16 (A), 1 (B), and 5 M (C) for MRP1; 2 (D), 20 (E), and 200 M (F) for MRP2, 0.08 (G), 1 (H), and 5 M (I) for MRP3, and 0.1 (J), 0.3 (K),
and 1 M (L) for MRP4. ATP-dependent transport was determined after 5 min for MRP1, MRP2, and MRP4 and after 2 min for MRP3. Transport rates are expressed
as a percentage of uptake measured in the absence of the CB1 receptor antagonist tested against the log drug concentration. Two to three independent experiments were
performed in duplicate. The mean  S.E.M. of n  3 to 6 is shown.
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the CB1 receptor, ED50 values of 0.14, 0.02, and 0.15 mg/kg, respec-
tively, would have been expected. However, the actual ED50 values of
compounds 4, 11, and 14 (Table 2) were 	2, 10, and 4.7 times
higher than expected, indicating a lower brain permeability compared
with that for compound 15.
Discussion
This study shows that CB1 receptor antagonists interacted with the
efflux transporters MRP1, MRP2, MRP3, and MRP4. E217G was
used as a model substrate to investigate the effect of CB1 receptor
antagonists on transport activity of these transporters. The kinetic
parameters for E217G found in this study were comparable to those
in the literature (Loe et al., 1996; Zeng et al., 2000; Chen et al., 2001).
Unlike MRP1, MRP3, and MRP4, MRP2 transported E217G in a
positive cooperative manner, which was previously demonstrated by
others (Bodo´ et al., 2003a; Zelcer et al., 2003).
Actual tested concentrations of the very lipophilic CB1 receptor
antagonists in the experimental assays were determined by LC-
MS/MS and were 3- to 100-fold lower than expected. This result may
be due to incomplete dissolution or nonspecific binding. In our study,
compounds 15 to 17 stimulated MRP2 better than compounds 4 to 14
at low concentrations. In contrast, the opposite was found at higher
concentrations, at which the actual concentrations of compounds 15 to
17 were lower (1–3 M) than those of 4 to 14 (7–33 M) (Fig. 3).
This result indicates that compounds 15 to 17, which contain N-
substituents that make them more lipophilic, have a higher potency in
affecting MRP2 but have a limited effect because of their low solu-
bility. The same was found for MRP3, and the lack of effect of
compounds 15 to 23 on MRP1 and MRP4 might also be explained by
their low actual concentrations.
Although we used E217G as a substrate for all transporters, the
effect of the CB1 receptor antagonists on transport of this substrate via
MRP1–4 was different. MRP1- and MRP4-mediated transport was
inhibited by several CB1 receptor antagonists. The inhibitory affinity
of rimonabant was somewhat higher for MRP1-mediated E217G
transport than for MRP4-mediated transport, with a Ki of 1.4 M
versus 4 M. The maximal plasma concentration found in male
human subjects treated with a therapeutic dose of rimonabant is 0.4
M (Turpault et al., 2006). Rimonabant and 3,4-diarylpyrazoline 13
appeared to inhibit MRP1 and MRP4 in a noncompetitive manner
(Fig. 5, A–C). In addition, MRP1 and MRP4 were stimulated at low
substrate and rimonabant concentrations, indicating that rimonabant
probably does not compete for the E217G binding site of either
transporter (Fig. 4, A and J). Whether rimonabant and the 3,4-
diarylpyrazolines are only inhibitors or are also substrates of MRP1 or
MRP4 cannot be concluded from this study.
In contrast to MRP1 and MRP4, MRP2-mediated transport was
stimulated by all CB1 receptor antagonists, except for compound 23.
The results presented in this study suggest that 3,4-diarylpyrazolines
and rimonabant stimulate MRP2 allosterically at low E217G con-
centrations and compete for the E217G binding site at high concen-
trations. This type of interaction is supported by other studies (Bakos
et al., 2000; Evers et al., 2000; Zelcer et al., 2003). The study of Zelcer
et al. (2003) showed that several aromatic compounds, most of them
containing sulfoxide or tosyl groups, stimulate MRP2-mediated trans-
port of E217G into membrane vesicles. Compounds that normalized
the stimulated transport rates at increasing concentrations, such as
sulfinpyrazone and indomethacin, also appeared to be substrates for
MRP2 (Evers et al., 2000; Zelcer et al., 2003). 3,4-Diarylpyrazolines
chemically resemble sulfinpyrazone, which, together with the fact that
compounds 13 and 15 and rimonabant might compete with E217G at
higher substrate concentrations, could indicate that they are substrates
for MRP2.
The CB1 receptor antagonists had comparable effects on MRP3
transport activity, but their effects were less pronounced than those for
MRP2 (Fig. 4, G–I). Other studies reported that MRP3-mediated
E217G transport activity can be inhibited as well as stimulated by
different compounds, e.g., 6-hydroxy-5,7-dimethyl-2-methylamino-4-
(3-pyridylmethyl) benzothiazole (E3040) sulfate, indomethacin, and
benzbromarone (Akita et al., 2002; Bodo´ et al., 2003a,b). This result
indicates that the 3,4-diarylpyrazolines and rimonabant would interact
TABLE 2
Pharmacodynamic characteristics of the CB1 receptor antagonists
Compound CB1rb (Ki)a ED50b
nM mg/kg i.v.
4 223  103 	0.3
11 30  14 0.2
14 231  66 0.7
15 155  69 0.1
a CB1rb, displacement of specific CP55,940 binding in CHO cells stably transfected with
human CB1 receptor, expressed as Ki  S.E.M. Data were adapted from Lange et al. (2005).
b Dose of CB1 receptor antagonist that attenuates CP55,940-induced hypotension in rats (n
2/dose) by 50%.
FIG. 5. Dixon plots of inhibition of MRP1- and MRP4-mediated ATP-dependent
E217G transport by rimonabant and 3,4-diarylpyrazoline 13. The reciprocal of
transport velocity (1/V) of different substrate concentrations is plotted against the
inhibitor concentration. Dixon plots of inhibition of MRP1 (A) and MRP4 (B) by
rimonabant and of MRP4 by compound 13 (C) at three different E217G concen-
trations are shown [0.16 M (F), 1 M (), and 5 M (Œ) E217G MRP1 for
MRP1 and 0.1 M (f), 0.3 M (‚), and 1 M () E217G for MRP4]. Linear
regression analysis was used for plotting lines and determination of Ki. Data
represent the mean 1/V of duplicate measurements in a representative experiment.
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with a modulating site and the substrate site of MRP3, causing
stimulation of E217G transport at low substrate concentrations and
inhibition at higher substrate concentrations because of competition
for the substrate site.
Our results show that rimonabant and 3,4-diarylpyrazolines can
modulate MRP1–4 transport activity, which implies the possibility of
drug-drug interactions. Because of the brief clinical use of rimon-
abant, few data are available on its in vivo interaction potential with
drug transporters. Rimonabant was found to moderately affect the
pharmacokinetics of the P-glycoprotein (ABCB1) substrate cyclo-
sporine, but not of tacrolimus and digoxin (Kanamaluru et al., 2005;
Amundsen et al., 2009).
The pharmacokinetic data available for rimonabant do not suggest
an important role for the MRPs in determining its disposition. Rimon-
abant is shown to accumulate in fat tissue, spleen, thyroid, thymus,
liver, plasma, and brain and is reported to cross the placental barrier
(Barna et al., 2009) (European Medicines Agency-European Public
Assessment Reports scientific discussion about rimonabant, http://
www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_
Scientific_Discussion/human/000666/WC500021284.pdf). Al-
though rimonabant showed a strong interaction with MRP1, its accu-
mulation in the brain and passage across the placental barrier indicates
that it is either a poor substrate of this transporter, or MRP1 is not
efficacious enough as a barrier for rimonabant.
MRP1 and MRP4 are expressed at the blood-brain-barrier and the
choroid plexus, where these transporters could be involved in limiting
the brain penetration of the 3,4-diarylpyrazoline CB1 receptor antag-
onists. Because there are only minor differences in the structures of
the 3,4-diarylpyrazolines, the rate and extent of passive diffusion of
these compounds into the brain and other tissues is expected to be
similar, which should reflect in a similar relationship between ED50
and CB1 receptor binding affinity (Ki). However, there was a differ-
ence in ED50 values for compounds 4, 11, 14, and 15, which could not
solely be attributed to differences in CB1 receptor binding affinities.
The ED50 values of compounds 4, 11, and 14 relative to their Ki
values were higher compared with the ED50/Ki ratio of compound 15
(Table 2). This finding suggests that an active mechanism is lowering
the concentration of compounds 4, 11, and 14 at the site of action,
resulting in increased ED50 values. The rapid hypotensive action of
CB1 receptor agonists was shown to be primarily dependent on
centrally mediated sympathetic tone (Vollmer et al., 1974), which
could indicate that compounds 4, 11, and 14 but not 15 have higher
ED50 values because they are less brain-permeable. Our in vitro data
suggest that MRP4 might be involved. To draw definite conclusions
about the involvement of MRP1–4 in influencing tissue concentra-
tions of 3,4-diarylpyrazolines, in vivo studies should be performed
using specific transport inhibitors and/or Mrp knockout mice.
In addition, it will be important to measure direct transport of CB1
receptor antagonists by MRP1–4 in vitro. Isolated membrane vesicles are
probably not useful for this purpose because of the high nonspecific
binding to lipid membranes and high passive diffusion of the lipophilic
CB1 receptor antagonists (H. G. M. Wittgen, J. B. Koenderink, and
F. G. M. Russel, unpublished results). Cell-based accumulation or vec-
torial transport studies may be more suitable. Furthermore, the role of the
blood-brain barrier and intestinal ABC transporters P-gp and breast
cancer resistance protein (ABCG2) as possible CB1 receptor antagonist
efflux pumps should be investigated. The role of influx transporters
should also be considered in the tissue distribution of the CB1 receptor
antagonists, but it is to be expected that uptake of these lipophilic
compounds will be governed largely by passive diffusion.
In conclusion, we have shown that 3,4-diarylpyrazolines and ri-
monabant inhibited MRP1- and MRP4-mediated E217G transport
and stimulated MRP2- and MRP3-mediated transport at low E217G
concentrations. Stimulation of MRP2 and MRP3 shifted to inhibition
at increasing substrate concentrations. The effect of these compounds
on the transport activity of MRP1–4 shows the potential for possible
drug-drug interactions. Preliminary in vivo data suggested that MRP4
could be involved in the lower brain permeability of some of the
3,4-diarylpyrazolines. The actual role of MRPs in tissue distribution
of 3,4-diarylpyrazolines and rimonabant remains to be investigated. In
addition, this study shows that the modulatory effects of the 3,4-
diarylpyrazolines were influenced by the properties of their N-sub-
stituent, which indicates that small variations in their chemical struc-
ture can determine the affinity for the efflux transporters and thereby
possibly affect their pharmacokinetic behavior.
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